Evidence map›Paper›PMID 36249048›Full record

ArticleFrontiers in oncology2022

Fully automated detection and localization of clinically significant prostate cancer on MR images using a cascaded convolutional neural network.

Lina Zhu, Ge Gao, Yi Zhu, Chao Han, Xiang Liu, Derun Li, Weipeng Liu, Xiangpeng Wang, Jingyuan Zhang, Xiaodong Zhang and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Diagnostic value of [Frontiers in oncology · 2025
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Lina ZhuDepartment of Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Ge GaoDepartment of Radiology, Peking University First Hospital, Beijing, China.
Yi ZhuDepartment of Clinical & Technical Support, Philips Healthcare, Beijing, China.
Chao HanDepartment of Radiology, Peking University First Hospital, Beijing, China.
Xiang LiuDepartment of Radiology, Peking University First Hospital, Beijing, China.
Derun LiDepartment of Urology, Peking University First Hospital, Beijing, China.
Weipeng LiuDepartment of Development and Research, Beijing Smart Tree Medical Technology Co. Ltd., Beijing, China.
Xiangpeng WangDepartment of Development and Research, Beijing Smart Tree Medical Technology Co. Ltd., Beijing, China.
Jingyuan ZhangDepartment of Development and Research, Beijing Smart Tree Medical Technology Co. Ltd., Beijing, China.
Xiaodong ZhangDepartment of Radiology, Peking University First Hospital, Beijing, China.
Xiaoying WangDepartment of Radiology, Peking University First Hospital, Beijing, China.
Peking University · CNFirst Affiliated Hospital of Zhengzhou University · CNPhilips (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To develop a cascaded deep learning model trained with apparent diffusion coefficient (ADC) and T2-weighted imaging (T2WI) for fully automated detection and localization of clinically significant prostate cancer (csPCa). Methods: This retrospective study included 347 consecutive patients (235 csPCa, 112 non-csPCa) with high-quality prostate MRI data, which were randomly selected for training, validation, and testing. The ground truth was obtained using manual csPCa lesion segmentation, according to pathological results. The proposed cascaded model based on Res-UNet takes prostate MR images (T2WI+ADC or only ADC) as inputs and automatically segments the whole prostate gland, the anatomic zones, and the csPCa region step by step. The performance of the models was evaluated and compared with PI-RADS (version 2.1) assessment using sensitivity, specificity, accuracy, and Dice similarity coefficient (DSC) in the held-out test set. Results: In the test set, the per-lesion sensitivity of the biparametric (ADC + T2WI) model, ADC model, and PI-RADS assessment were 95.5% (84/88), 94.3% (83/88), and 94.3% (83/88) respectively (all p > 0.05). Additionally, the mean DSC based on the csPCa lesions were 0.64 ± 0.24 and 0.66 ± 0.23 for the biparametric model and ADC model, respectively. The sensitivity, specificity, and accuracy of the biparametric model were 95.6% (108/113), 91.5% (665/727), and 92.0% (773/840) based on sextant, and were 98.6% (68/69), 64.8% (46/71), and 81.4% (114/140) based on patients. The biparametric model had a similar performance to PI-RADS assessment (p > 0.05) and had higher specificity than the ADC model (86.8% [631/727], p< 0.001) based on sextant. Conclusion: The cascaded deep learning model trained with ADC and T2WI achieves good performance for automated csPCa detection and localization.

Indexed as

deep learningdetectionlocalizationmagnetic resonance imagingprostatic neoplasms

Identifiers

PMID36249048
PMCPMC9558117
OpenAlexW4297999149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.